PA
GDRX icon

PharVision Advisers’s GoodRx Holdings GDRX Stock Holding History

PharVision Advisers’s Portfolio GDRX Stock Details GDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-126,424
Closed -$343K – 321
2025
Q4 		$343K Buy
126,424
+85,687
+210% +$281K 0.17% 203
2025
Q3 		$172K Buy
+40,737
New +$179K 0.1% 550

Other funds holding GDRX

FPM
Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SLG
Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

PharVision Advisers's GDRX Position: Q1 2026 in Review

PharVision Advisers sold out of GoodRx Holdings (GDRX) in Q1 2026, closing a stake of 126,424 shares — an estimated $343K sold.

PharVision Advisers first reported a position in GDRX in Q3 2025 and held it in 2 quarters. The position peaked at $343K in Q4 2025. 174 funds tracked by Wall St. Rank hold GDRX as of Q1 2026.

  • PharVision Advisers reported no remaining GoodRx Holdings position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 126,424 GoodRx Holdings shares in Q1 2026, an estimated $343K.
  • PharVision Advisers first reported a position in GoodRx Holdings in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's GoodRx Holdings position peaked at $343K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.